Recent studies, including the EXXELERATE post hoc analysis, have shown that certolizumab-treated patients with RA and high RF had similar drug concentrations and clinical responses to patients with RA and low RF levels, a pattern not observed in patients treated with other Fc-containing TNFis.^5,11,13

These data suggest that RF levels should be considered when making treatment decisions for patients with RA, and that certolizumab may be a suitable therapy for patients with RA and high RF.¹⁴